FrancophonIA/ELRC3.0 huggingface dataset:
English: Established susceptibility breakpoints for systemic (oral or intravenous) administration of levofloxacin are not applicable to delivery by inhalation.
Croatian: Utvrđene granične vrijednosti osjetljivosti za sistemsku (peroralnu ili intravensku) primjenu levofloksacina nisu primjenjive za primjenu u obliku inhalacije.
English: N = 93 90.5 days
Croatian: N = 93 90,5 dana
English: - Glucose-6-phosphate dehydrogensae deficiency Quinolone antibiotics, such as Quinsair, can cause patients with glucose-6-phosphate dehydrogenase deficiency (a rare hereditary disease) to be prone to blood complications leading to a sudden rise in body temperature, yellowing of the skin and mucous membranes, dark coloured urine, paleness, tiredness, heavy, fast breathing and a weak, rapid pulse.
Croatian: Kinolonski antibiotici, poput Quinsaira, mogu u bolesnika s deficitom glukoza-6-fosfatdehidrogenaze (rijetkom nasljednom bolešću) uzrokovati sklonost krvnim komplikacijama koje dovode do iznenadnog porasta tjelesne temperature, žuto obojene kože i sluznica, tamne mokraće, bljedoće, umora, teškog, ubrzanog disanja i slabog, ubrzanog pulsa.
English: Serious haematological adverse reactions such as pancytopenia, agranulocytosis and haemolytic anaemia have been reported following systemic administration of levofloxacin.
Croatian: Ozbiljne hematološke nuspojave poput pancitopenije, agranulocitoze i hemolitičke anemije prijavljeni su nakon sistemske primjene levofloksacina.
English: Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following active substances: calcium carbonate, digoxin, glibenclamide and ranitidine.
Croatian: Klinička farmakološka ispitivanja pokazala su da, u klinički značajnoj mjeri, nema utjecaja na farmakokinetiku levofloksacina kada se levofloksacin primjenjuje zajedno sa sljedećim djelatnim tvarima: kalcijev karbonat, digoksin, glibenklamid i ranitidin.
English: On the front of the ampoule tail Quinsair 240 mg
Croatian: Na prednjoj strani „repa“ ampule Quinsair 240 mg
English: ON Quinsair Use it twice a day for 28 days
Croatian: POD TERAPIJOM Quinsairom Primijenite dva puta na dan kroz 28 dana
English: Therefore, doses of Quinsair do not need to be adjusted in patients with mild to moderate renal impairment.
Croatian: Stoga nije potrebno prilagođavanje doze Quinsaira u bolesnika s blagim do umjerenim oštećenjem bubrega.
English: Fluoroquinolones have been shown to cause arthropathy in weight-bearing joints of immature animals.
Croatian: Utvrđeno je da fluorokinoloni uzrokuju artropatiju u težinom opterećenim zglobovima nezrelih životinja.
English: If you experience palpitations or an irregular heart beat whilst using Quinsair you should tell your doctor immediately.
Croatian: Ako osjetite lupanje srca ili nepravilne otkucaje srca dok koristite Quinsair, morate o tome obavijestiti svog liječnika.
English: At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with levofloxacin should be discontinued and alternative treatment should be considered.
Croatian: Kod prvog znaka tendinitisa (npr. bolan otok, upala) treba prekinuti liječenje levofloksacinom i razmotriti primjenu druge terapije.
English: Transient vision loss
Croatian: prolazni gubitak vida
English: Tabulated list of additional adverse reactions reported following systemic administration of levofloxacin
Croatian: Tablični prikaz dodatnih nuspojava prijavljenih nakon sistemske primjene levofloksacina
English: Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).
Croatian: Stoga je potrebno pratiti parametre koagulacije u bolesnika liječenih antagonistima vitamina K (vidjeti dio 4,4).
English: Once an ampoule is opened, the contents should be used immediately.
Croatian: Nakon otvaranja ampule, njezin sadržaj se mora odmah iskoristiti.
English: Multiple dose administration of Quinsair 240 mg twice daily by inhalation results in levofloxacin systemic exposure approximately 50% lower than that observed following systemic administration of comparable doses (see Table 3).
Croatian: Višekratna primjena Quinsair 240 mg dva puta na dan putem inhalacije rezultirala je sustavnom izloženošću levofloksacinu oko 50% nižom od one primijećene nakon sistemske primjene usporedivih doza (pogledati tablicu 3).
English: Studies using systemic administration of levofloxacin show that the pharmacokinetics of levofloxacin are affected by renal impairment; with decreasing renal function (estimated creatinine clearance < 50 ml/min), renal elimination and clearance are decreased, and elimination half-life increased.
Croatian: Ispitivanja u kojima se koristila sistemska primjena levofloksacina pokazala su da oštećenje bubrega utječe na farmakokinetiku levofloksacina; smanjenjem bubrežne funkcije (procijenjen klirens kreatinina < 50 ml/min), bubrežna eliminacija i klirens se smanjuju a poluvijek eliminacije produljuje.
English: Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.
Croatian: Bolesnicima je potrebno savjetovati da prekinu liječenje i obrate se svom liječniku ako se kod njih pojave znakovi i simptomi bolesti jetre, poput anoreksije, žutice, tamne mokraće, svrbeža ili osjetljivog abdomena.
English: 5th Inhaled steroids
Croatian: Quinsair inhalacijske steroide
English: However, there is variability in the systemic exposures observed which means that serum levels of levofloxacin following inhalation of Quinsair may sometimes fall within the range of levels observed following systemic administration of comparable doses.
Croatian: Međutim, primijećena sustavna izloženost je varijabilna, što znači da razina levofloksacina u serumu nakon inhalacije Quinsaira može biti unutar raspona razina primijećenih nakon sistemske primjene usporedivih doza.
English: Patients weighing 22 to 30 kg received 180 mg levofloxacin/day and patients weighing ˃ 30 kg received 240 mg levofloxacin/day.
Croatian: Bolesnici tjelesne težine 22 do 30 kg primala su 180 mg levofloksacina/dan a bolesnici tjelesne težine ˃ 30 kg primala su 240 mg levofloksacina/dan.
English: The apparent clearance (CL/F) of levofloxacin following inhalation of Quinsair 240 mg twice daily is 31.8 +/- 22.4 L/hour.
Croatian: Prividni klirens (CL/F) levofloksacina nakon inhalacije Quinsaira 240 mg dva puta na dan iznosi 31,8 +/- 22,4 l/sat.
English: INFORMATION IN BRAILLE Quinsair
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Quinsair
English: More detailed instructions are available in the Package Leaflet and device Manufacturer's Instructions for Use.
Croatian: Detaljnije upute dostupne su u Uputi o lijeku i Uputama proizvođača za uporabu sustava za inhalaciju.
English: Taking Quinsair at the same time as these medicines could affect how your kidneys deal with the medicine which is particularly important if you suffer from kidney problems.
Croatian: Istodobno korištenje Quinsaira i tih lijekova može utjecati na izlučivanje lijeka bubrezima, što je osobito važno ako patite od problema s bubrezima.
English: Please refer to the Manufacturer's Instructions for Use for cleaning and storage advice.
Croatian: Molimo potražite u Uputama proizvođača za uporabu savjete kako čistiti i čuvati sustav za inhalaciju.
English: Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin).
Croatian: Povećanje parametara koagulacije (PT/INR) i/ili krvarenja, koje može biti ozbiljno, zabilježeno je u bolesnika koji su liječeni levofloksacinom u kombinaciji s antagonistima vitamina K (npr. varfarinom).
English: Table 3: Comparison of mean (SD) multiple dose levofloxacin pharmacokinetic parameters following Quinsair administration by inhalation to patients with CF and following oral and intravenous administration of levofloxacin to healthy adult volunteers
Croatian: Tablica 3: Usporedba farmakokinetičkih parametara srednje (SD) višekratne doze levofloksacina nakon inhalacijske primjene Quinsaira u bolesnika s CF i nakon peroralne i intravenske primjene levofloksacina u zdravih odraslih dobrovoljaca
English: Do not use this medicine after the expiry date which is stated on the ampoule, the foil sachet and the boxes after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na ampuli, vrećici i kutijama iza oznaka „Rok valjanosti“ ili „EXP“.
English: However, dose adjustments were not employed in clinical studies of Quinsair which allowed for the inclusion of patients with mild to moderate renal impairment (estimated creatinine clearance ≥ 20 ml/min using the Cockcroft-Gault formula in adult patients and ≥ 20 ml/min/1.73 m2 using the Bedside Schwartz formula in patients < 18 years old).
Croatian: Međutim, prilagodbe doze nisu primjenjivane tijekom kliničkih ispitivanja Quinsaira što je omogućilo uključivanje bolesnika s blagim do umjerenim oštećenjem bubrega (klirens kreatinina ≥ 20 ml/min procijenjen pomoću Cockcroft--Gaultove formule u odraslih bolesnika i ≥ 20 ml/min/1,73 m2 procijenjenog pomoću Bedside Schwartzove formule u bolesnika u dobi od
English: Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium difficile-associated disease (CDAD).
Croatian: Dijareja koja se javi tijekom ili nakon liječenja levofloksacinom (uključujući i nekoliko tjedana nakon liječenja), osobito ako je teška, uporna i/ili krvava, može biti simptom bolesti povezane s Clostridium difficile (engl.
English: Quinsair is used to treat lung infections caused by Pseudomonas aeruginosa in adults with cystic fibrosis.
Croatian: Quinsair se koristi za liječenje infekcija pluća uzrokovanih Pseudomonas aeruginosa u odraslih koji imaju cističnu fibrozu.
English: 2) Squeeze all of the contents of one ampoule into the medicine reservoir of the Zirela Nebuliser Handset (Figure 1).
Croatian: 2) Istisnite sadržaj jedne ampule u spremnik naprave za inhalaciju Zirela Nebuliser Handset (slika 1).
English: Quinsair should be taken by inhalation using a Zirela Nebuliser Handset (including a Zirela Aerosol Head).
Croatian: Quinsair se mora primjenjivati inhalacijom pomoću naprave za inhalaciju Zirela Nebuliser Handset (uključujući Zirela Aerosol Head).
English: - Photosensitivity
Croatian: - Fotoosjetljivost
English: N = 93 110 days
Croatian: N = 93 110 dana
English: Uncommon: may affect up to 1 in 100 people - Fungal infection of the mouth - Low numbers of red cells in the blood (anaemia) or the cells in the blood that help it clot
Croatian: Manje često: mogu se javiti kod najviše 1 na 100 osoba - gljivične infekcije u ustima - nizak broj crvenih krvnih stanica u krvi (anemija) ili stanica koje sudjeluju u zgrušavanju krvi
English: ** See paragraph below for further details.
Croatian: ** Za više podataka pogledati paragraf u nastavku.
English: However if there are more than a few drops left, replace the medicine cap and restart treatment.
Croatian: Međutim, ako je zaostalo više od nekoliko kapljica, vratite poklopac spremnika na mjesto i ponovite postupak.
English: Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF, see section 5.1).
Croatian: Quinsair je indiciran za liječenje kroničnih plućnih infekcija uzrokovanih Pseudomonas aeruginosa u odraslih bolesnika s cističnom fibrozom (CF, vidjeti dio 5.1).
English: Airway clearance techniques;
Croatian: Tehnike za pročišćavanje dišnih puteva;
English: Study 207 (ITT)
Croatian: Potporna ispitivanja Ispitivanje 207 (ITT)
English: N = 189 141 days
Croatian: N = 189 141 dana
English: Table 1: FEV1 Percent predicted relative change from baseline to Day 28 in placebo-controlled efficacy and safety studies of Quinsair in patients with CF
Croatian: Tablica 1: Relativna promjena od početne vrijednosti postotka predviđene vrijednosti FEV1 do 28. dana u placebom kontroliranom ispitivanju djelotvornosti i sigurnosti primjene Quinsaira u bolesnika s CF
English: In addition, 14 children with CF (≥ 6 to < 12 years old) and 13 adolescents with CF (≥ 12 to < 17 years old) received Quinsair 180 mg or 240 mg once daily for 14 days.
Croatian: Nadalje, 14 djece s CF (u dobi od ≥ 6 do < 12 godina) i 13 adolescenata s CF (u dobi od ≥ 12 do < 17 godina) primala su Quinsair 180 mg ili 240 mg jedan put na dan tijekom 14 dana.
English: 2) Hold the handset level, press and hold the on/off button on the controller for a few seconds.
Croatian: 2) Pridržavajte uređaj u razini, pritisnite i držite nekoliko sekundi pritisnutom tipku za uključivanje (on/off) na kontroloru protoka.
English: If a dose is missed, it should be taken as soon as the patient remembers providing that at least an 8 hour interval is allowed before inhaling the next dose.
Croatian: Ako se doza preskoči, lijek se treba uzeti čim se bolesnik toga sjeti, pod uvjetom da mora proći najmanje 8 sati prije sljedeće doze.
English: For the subgroup of patients who received TIS during the Core Phase and switched to Quinsair in the Extension Phase, the improvement in FEV1 percent predicted was more marked on Quinsair than on TIS (LS Mean change in FEV1 percent predicted on TIS ranged between 0.97% to 3.60% across Cycles 1 to 3 and between 4.00% to 6.91% across Cycles 4 to 6 on Quinsair).
Croatian: U podskupini bolesnika koji su primali TIS tijekom središnje faze ispitivanja i prebačeni su na Quinsair u produljenoj fazi, poboljšanje postotka FEV1 predviđene vrijednosti bilo je izraženije u skupini Quinsair nego u skupini TIS (srednja LS promjena postotka predviđene vrijednosti FEV1 u skupini TIS kretala se između 0,97% i 3,60% od 1. do 3. ciklusa i između 4,00% i 6,91% od 4. do 6. ciklusa terapije Quinsairom).
English: It reduced tumour development in a photocarcinogenicity study.
Croatian: U ispitivanju fotokancerogenosti smanjio je razvoj tumora.
English: Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study.
Croatian: Teofilin, fenbufen ili slični nesteroidni protuupalni lijekovi U kliničkom ispitivanju nisu utvrđene farmakokinetičke interakcije levofloksacina s teofilinom.
English: How to use Quinsair
Croatian: Kako koristiti Quinsair
English: Patients predisposed to seizures
Croatian: Bolesnici s predispozicijom za napadaje
English: Adult and adolescent (≥ 12 to < 18 years old and weighing ≥ 30 kg) patients who had a FEV1 percent predicted between 25% and 85% were enrolled.
Croatian: U ispitivanje su bili uključeni odrasli bolesnici i adolescenti (u dobi od ≥ 12 do < 18 godina i tjelesne težine ≥ 30 kg) kod kojih je postotak FEV1 bio između 25% i 85% predviđene vrijednosti.
English: • Concomitant use of active substances that are known to prolong the QT interval (e.g. Class IA
Croatian: • Istodobne primjene djelatnih tvari za koje je poznato da produljuju QT-interval (npr.
English: Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide.
Croatian: Levofloksacin se metabolizira u vrlo malom opsegu, a metaboliti su mu desmetil-levofloksacin i levofloksacin-N-oksid.
English: What Quinsair contains - The active substance is levofloxacin.
Croatian: Što Quinsair sadrži - Djelatna tvar je levofloksacin.
English: - Coughing up blood or blood-stained mucus from the airways.
Croatian: - iskašljavanje krvi ili sluzi s tragovima krvi iz dišnih puteva
English: The proportion of patients who received Quinsair throughout Study 209 Core and Extension Phases (with a highest levofloxacin MIC P. aeruginosa isolate exceeding 1 µg/ml) was similar at the end of treatment during Cycles 1 and 3 in the Core Phase (76.6% to 83.3%) and at the end of treatment during Cycles 4 to 6 in the Extension Phase (77.8% to 87.5%).
Croatian: Omjer bolesnika koji su primali Quinsair tijekom čitave središnje i produljene faze Ispitivanja 209 (i imali najvišu MIC levofloksacina za izolat P. aeruginosa koja je prelazila 1 µg/ml), bio je sličan na kraju liječenja tijekom 1. i 3. ciklusa u središnjoj fazi ispitivanja (76,6% do 83,3%) i na kraju liječenja tijekom 4. do 6. ciklusa u produljenoj fazi ispitivanja (77,8% do 87,5%).
English: Hazard ratio [95% CI] d: P = 0.154 e
Croatian: Omjer hazarda [95% CI] d: P = 0,154 e
English: 3 ml, Low density polyethylene ampoule.
Croatian: Ampula od 3 ml od polietilena niske gustoće.
English: Post-marketing serious adverse reactions, including deaths and the requirements for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis.
Croatian: Ozbiljne nuspojave zabilježene nakon stavljanja lijeka na tržište, koje su uključivale smrt i potrebu za respiratornom potporom, smatrale su se povezane s primjenom fluorokinolona u bolesnika s miastenijom gravis.
English: Symptoms include: - Loss of appetite - Yellowing of the skin and eyes (jaundice) - Dark coloured urine - Itching - Tenderness (pain) around the stomach (abdomen)
Croatian: Simptomi uključuju: - gubitak apetita - žutu boju kože i očiju (žuticu) - tamno obojenu mokraću - svrbež - osjetljivost (bol) u području želuca (trbuha)
English: During the Extension Phase, the LS Mean change for FEV1 percent predicted ranged between 4.83% to 1.46% across the 3 additional treatment cycles.
Croatian: Tijekom produljene faze ispitivanja srednja promjena postotka predviđene vrijednosti FEV1 dobivena metodom najmanjih kvadrata kretala se između 4,83% i 1,46% u sva 3 dodatna terapijska ciklusa.
English: Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis).
Croatian: Stoga se fluorokinoloni smiju primjenjivati samo nakon pažljive procjene omjera koristi i rizika i nakon razmatranja drugih mogućnosti liječenja u bolesnika s aneurizmatskom bolesti u obiteljskoj anamnezi, ili u bolesnika kojima je prethodno dijagnosticirana aneurizma i/ili disekcija aorte ili u kojih postoje drugi rizični faktori ili stanja koja predstavljaju predispoziciju za aneurizmu i disekciju aorte (npr. Marfanov sindrom, vaskularni oblik Ehlers-Danlosova sindrom, Takayasuov arteritis, arteritis orijaških stanica, Behcetova bolest, hipertenzija, poznata ateroskleroza).
English: Doses do not need to be adjusted in patients with mild to moderate renal impairment (estimated creatinine clearance ≥ 20 ml/min using the Cockcroft-Gault formula).
Croatian: Nije potrebno prilagođavati dozu u bolesnika s blagim do umjerenim oštećenjem bubrega (klirens kreatinina ≥ 20 ml/min procijenjen pomoću Cockcroft-Gaultove formule).
English: However if it is nearly the time for your next dose, skip the missed dose.
Croatian: Vaše sljedeće doze, preskočite zaboravljenu dozu.
English: Disconnect the controller and dismantle the Zirela Nebuliser Handset for cleaning and disinfection.
Croatian: Odvojite kontrolor protoka i rastavite napravu za inhalaciju Zirela Nebuliser Handset radi čišćenja i dezinfekcije.
English: Hazard ratio [95% CI] d: P = 0.040 e
Croatian: Omjer hazarda [95% CI] d: P = 0,040 e
English: Photosensitisation has been reported with levofloxacin (see section 4.8).
Croatian: Fotosenzibilizacija je zabilježena pri primjeni levofloksacina (vidjeti dio 4.8).
English: Alanine aminotransferase increased, Aspartate aminotransferase increased, Pulmonary function test decreased*, Blood glucose increased and decreased*, Blood creatinine increased* Breath sounds abnormal*
Croatian: povišena alaninaminotransferaza, povišena aspartataminotransferaza, smanjeni rezultat testa plućne funkcije*, povišena i snižena glukoza u krvi*, povišen kreatinin u krvi* neuobičajeni plućni zvukovi*
English: * See paragraph below for further details.
Croatian: * Za više podataka pogledati paragraf u nastavku.
English: Due to possible increases in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these active substances are given concomitantly (see section 4.5).
Croatian: Zbog mogućeg porasta vrijednosti parametara koagulacije (PT/INR) i/ili krvarenja u bolesnika koji se liječe levofloksacinom u kombinaciji s antagonistima vitamina K (npr. varfarinom), potrebno je pratiti vrijednosti koagulograma kada se te djelatne tvari primjenjuju istodobno (vidjeti dio 4.5).
English: Fatigue/asthenia, Exercise tolerance decreased
Croatian: umor/astenija, smanjena tolerancija napora pireksija
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients Magnesium chloride hexahydrate Water for injections
Croatian: 6.1 Popis pomoćnih tvari magnezijev klorid heksahidrat voda za injekcije
English: if you have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular EhlersDanlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet's disease, high blood pressure, or known atherosclerosis).
Croatian: ako u obiteljskoj povijesti bolesti imate aneurizmu aorte ili disekciju aorte, ili druge rizične faktore ili stanja zbog kojih ste skloniji pojavi aneurizme ili disekcije (npr. poremećaji vezivnog tkiva kao što je Marfanov sindrom ili vaskularni oblik Ehlers-Danlosova sindrom ili vaskularni poremećaji kao što je Takayasuov arteritis, arteritis orijaških stanica, Behcetova bolest, visoki krvni tlak ili poznata ateroskleroza).
English: and decreased kidney function test) - Decreased lung function test - Increased or decreased amount of sugar (glucose) in the blood - Abnormal breathing sounds
Croatian: smanjeni rezultati funkcionalnih bubrežnih testova) - smanjeni rezultati funkcionalnih plućnih testova - povišena ili snižena razina šećera (glukoze) u krvi - nenornalni zvuk disanja
English: If you stop using Quinsair Do not stop using Quinsair without first talking to your doctor as your lung infection may worsen.
Croatian: Nemojte prestati primjenjivati Quinsair a da se prethodno niste savjetovali s liječnikom jer se Vaša plućna infekcija može pogoršati.
English: Quinsair is administered by inhalation over a 5 minute period using a Quinsair specific Zirela Nebuliser Handset and Zirela Aerosol Head connected to an eBase Controller or an eFlow rapid Control Unit (see section 4.2).
Croatian: Quinsair se primjenjuje inhalacijom tijekom 5 minuta pomoću specifičnih naprava za inhalaciju Quinsaira, Zirela Nebuliser Handset i Zirela Aerosol Head, spojenih na kontrolor protoka eBase Controller ili eFlow rapid Control Unit (vidjeti dio 4.2).
English: It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium) during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.
Croatian: Preporučuje se da se bolesnici tijekom liječenja i 48 sati nakon prekida liječenja nepotrebno ne izlažu prejakoj sunčevoj svjetlosti ili umjetnim izvorima UV zraka (npr. lampe koje emitiraju UV zrake, solarij) kako bi se spriječila fotosenzibilizacija.
English: Visual disturbance*
Croatian: smetnje vida*
English: - Do not use Quinsair if you notice that it is cloudy or there are particles in the solution.
Croatian: - Ne koristite Quinsair ako primijetite da je otopina zamućena ili da sadrži čestice.